(Gentamicin + pentetic acid) is under clinical development by Hoth Therapeutics and currently in Phase I for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase I drugs for Atopic Dermatitis (Atopic Eczema) have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Gentamicin + pentetic acid)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Gentamicin + pentetic acid) overview
Gentamicin in combination with pentetic acid (DTPA) is under development for the treatment of atopic dermatitis. It is applied topically as a cream. DTPA acts by chelating Zinc (Zn) whereas gentamicin acts by targeting 16S ribosomal RNA. It is developed based on BioLexa platform technology. It was under development for diabetic foot ulcers and chronic deep wounds.
Hoth Therapeutics overview
Hoth Therapeutics is engaged in clinical stage drug development related activities for producing new generation drugs, vaccines and therapies for dermatological disorders that in turn offers enhanced quality and healthy life for its patients suffering with atopic dermatitis, chronic wounds, psoriasis, asthma and acne related conditions. The company is headquartered in New York, the US.
For a complete picture of (Gentamicin + pentetic acid)’s drug-specific PTSR and LoA scores, buy the report here.